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The advent of monoclonal antibody biosimilars [MABS] represents a 
serious challenge for the entire landscape of biologicals in medicine, 
with a series of interrogations for the healthcare community. The 
first serious interrogation was to establish if the industry was able to 
reproduce entire antibodies, multimeric glycosylated proteins, from 
the originator product on the market. The very exhaustive and com-
prehensive comparability exercise conducted to demonstrate CT-P13 
biosimilarity to infliximab, meeting all the stringent requirements 
requested for European Agency for the Evaluation of Medicinal 
Products [EMEA] approval, clearly showed that nowadays the tech-
nology exists to reproduce glycosylated monoclonal antibodies with 
a high standard of biosimilarity.1
The second interrogation is the extrapolation of indications. 
The theoretical concern here is whether it is sufficient to test a 
MABS in one randomised trial at one dose in one indication to 
establish that this MABS will bring the same clinical benefits with 
the same safety in all the other indications of its originator. This 
question is valid only if there are theoretical reasons linked to 
the mode of action of the antibody, its dosing, or a feature of one 
indication yet untested, that make us believe that the MABS may 
show a previously unrecognised dissimilarity as compared with 
the originator. However, in the case of the first infliximab MABS 
CT-P13, which was tested without unusual signal in randomised 
trials in two indications covering the range of dosing of the origi-
nator, the likelihood of a disease-specific event to occur in a third 
indication decreases substantially. This debate is still ongoing.2,3 
Nevertheless, according to evidence-based medicine principles, 
each MABS should be studied in each further indication. Such 
later studies will participate in the demonstration of biosimilarity 
of the MABS and, perhaps more importantly, will contribute in 
pharmacovigilance regarding the new compound and its produc-
tion chain. Another dimension of Phase IV studies is to show that 
the efficacy and safety results of the trials are reproduced in clinical 
practice. The study by Krisztina Gecse et al., in the current issue of 
ECCO-JCC, contributes therefore original data to several aspects 
of the demonstration of biosimilarity of CT-P13.4 As the originator 
elicited higher frequencies of immunogenicity problems in imflam-
matory bowel disease [IBD] than in rheumatological indications, 
the absence of such signal in this prospective Phase IV study adds 
to the demonstration of the safety of CT-P13, even if larger studies 
are still needed.
At this stage, the most challenging issue remains pharmacovigi-
lance. Indeed, the arrival of the first MABS in the large field of 
immune-mediated inflammatory diseases [IMID] will probably affect 
the overall use of biologicals in these indications, far beyond its origi-
nator, to the other anti-tumour necrosis factor [TNF] agents and even 
to biologicals with other mechanisms of action. Indeed, in the absence 
of direct comparison trials among biologicals, there is no evidence to 
support the use of one biological over the others in most indications. 
If one compound, here infliximab, becomes much less expensive, it 
might be difficult for physicians, bound in all healthcare systems to 
provide cost-responsible care, to continue to make cost-independent 
choices, as is done currently with biologicals in the same price range. 
In some jurisdictions, switch to infliximab MABS is made practically 
mandatory by large tender systems.5 In others, hospital or insurance 
tender systems will lead choices. The presence of one cheap biological 
will put price pressure also on the other anti-TNFs to remain com-
petitive as they share most indications with infliximab.6 In turn, the 
pressure will extend to the other biologicals with similar indications, 
leading to a global price pressure. If large price differences persist, 
then there is a risk that third party payers seek to influence drug 
choices beyond the originator and its MABS.
This price pressure will push the biological drug producers to seek 
for savings along the drug production chain and the product testing 
process. This pressure will translate itself into an increased number 
of manufacturing changes, a number which will grow with the num-
ber of players and with the market expansion that lower prices will 
certainly also induce. As each manufacturing change carries a risk 
of introducing an unwanted alteration in the molecule or in its sur-
rounding dissolving solution, there will be a statistical growth of the 
likelihood of a problem to occur, with clinical impact on efficacy or 
in safety. There is a precedent of such a problem after the introduc-
tion of erythropoietin biosimilars.7 All physicians, regardless of their 
prescription habits towards biologicals, should thus participate in the 
pharmacovigilance effort that the regulators demand. Clinical nurses 
and pharmacists should also be involved. Several large databases are 
already available and disease-specific banks at the national and inter-
national levels are under development for this purpose.







The naming of MABS is also a current interrogation, in particu-
lar to help patients to know what they receive and in the traceability 
of the various products. Traditionally drugs are prescribed by their 
International Nonproprietary Name [INN], set by World Health 
Organization [WHO] rules. This organisation actively consults the 
various stakeholders to define INN rules for biologicals,8 whereas 
some national regulators have taken or are taking position. There is 
no clear answer here, as using the same INN for an originator and 
its MABS has advantages as much as drawbacks, and the use of 
several related INNs poses other problems. If naming is important, 
the real issue for biologicals pharmacovigilance might well be the 
traceability of manufacturing changes, which are not in the INN 
and not easily recovered by the user from lot numbers. To take the 
best advantage of the errors of the past and to follow the poten-
tial risks where they might occur, it may be just as important as a 
global naming policy to forward drug changes information to the 
end user. This strategy would help identify early a potential problem 
and thus lower the number of patients exposed, the ultimate goal of 
pharmacovigilance.
As drug development complexity will increase in the future, with 
advances not only in therapeutic antibody technology9 but possibly 
also in complete chemical synthesis,10 the maturation of the mecha-
nisms to monitor the safe introduction of new complex compounds 
in clinical care is a priority.
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